Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveVoriconazole pharmacokinetics in liver transplant recipients.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.Bench-to-bedside review: Candida infections in the intensive care unit.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Antifungal therapeutic drug monitoring: established and emerging indications.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Voriconazole therapeutic drug monitoring: focus on safety.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?Triazole antifungal agents in invasive fungal infections: a comparative review.Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors.Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxisPharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.Determination of Voriconazole Concentrations in Serum by GC-MS.Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories.Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.Tolerability profile of the current antifungal armoury.
P2860
Q27009221-D7CC7201-ECCB-4FBE-915D-4B1AE200449CQ33613685-33699E35-62CB-41C7-A198-7EF38E2F9EA6Q34309527-C157D5A9-8DA0-4474-B256-40E9CE0122E1Q35889014-5EB3242D-6301-4CD6-90B9-4BB4EEAF94EBQ36276895-A2003E54-F1B7-4578-8350-08468FB025FDQ36439011-0815960C-43E8-43DE-8DEA-6319709BDD00Q36641985-BE740A0E-568B-4A92-A659-C15E7557A0D6Q36849416-180F5E27-EADB-4979-A4A5-525C2B4E2485Q36927577-9FC4DA3F-26F9-4EAD-8A4E-7C75C18426D1Q37310029-ED88DCFA-DFE5-4CFA-95E4-1C4EA1F90BC2Q37469829-E7215C17-39A3-4B60-877A-9B2FBCEF9D2AQ37658869-A4CEFD68-B33A-4364-9B5D-9CCF33992764Q37816399-FB9EC807-0BD0-479F-B441-AAD25B54853FQ37863921-69645DB3-16D5-4F13-A855-7B530761F2C1Q37964703-A67B8918-3AD4-4D6D-A556-4924DB53B614Q38649042-306E9EF9-4141-447F-BB45-049517BE0ABDQ39215244-B241D5B6-0A41-4E2F-8F6C-24B8EEDF16BBQ39380410-D02A4957-4361-4185-BE22-600B0FAE9660Q39471624-B3D6EDBC-FF6E-41F7-B229-0AB4AB9D3CBEQ40982014-21D4E85E-DA07-4512-999F-86A24C0D1B0BQ41009508-C725B156-1B5F-4CF9-AB7A-6B6D52CA54B7Q41440955-8E3B31E0-4C5B-4238-BA96-5940299A2BF7Q41868987-50D2E22B-6ED6-474D-BE4E-10598AD38F2AQ41916356-1202EBFE-42E8-4E7E-AC26-E6033A528A20Q44106107-86947B58-0D91-4FDB-A256-C94017348A93Q44334907-CB61ED4C-C161-4385-8672-83F688151AD4Q46041840-3FE3D085-3553-4C54-A55B-B0896A4D5E12Q50170029-439F61BD-C613-4D23-A7DB-2AA591D74BE9
P2860
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Variability of voriconazole pl ...... tography and bioassay methods.
@ast
Variability of voriconazole pl ...... tography and bioassay methods.
@en
type
label
Variability of voriconazole pl ...... tography and bioassay methods.
@ast
Variability of voriconazole pl ...... tography and bioassay methods.
@en
prefLabel
Variability of voriconazole pl ...... tography and bioassay methods.
@ast
Variability of voriconazole pl ...... tography and bioassay methods.
@en
P2093
P2860
P50
P356
P1476
Variability of voriconazole pl ...... tography and bioassay methods.
@en
P2093
Andres Pascual
Jacques Bille
Oscar Marchetti
Paul A Majcherczyk
Saskia Bolay
Valérie Nieth
P2860
P304
P356
10.1128/AAC.00957-06
P407
P577
2006-11-06T00:00:00Z